Latest From Century Therapeutics
Private Company Edition: VC deals are surging this year for cell and gene therapy firms, according to ARM’s third quarter report. Also, Vivo Capital and the CF Foundation plan to invest nearly $2bn in health care and life science opportunities, and Akeso completes $150m series D.
Start-Up Quarterly Statistics: Financings Continue Quarterly Declines Despite Big Venture Deals And IPOs
A review of biopharma start-up dealmaking and financing activity from July through September 2019, based on data from Strategic Transactions. Fundraising activity fell 23% from the second to the third quarter, but start-up M&A surged, led by Vertex's acquisition of Semma.
Century Therapeutics brings in $250m for its cell therapy programs in a series A round, while immunotherapy specialist BioNTech sets a record for series B, raising $350m. Another five firms brought in rounds of $100m or greater...
Bayer’s VC LEAPS program invests in a second new biotech this month through its participation in the series A funding round for new immuno-oncology biotech Pyxis Oncology.
- Gene Therapy, Cell Therapy
- Therapeutic Areas
- North America
- Company Type
- Parent & Subsidiaries
- Century Therapeutics
- Senior Management
Lalo Flores, PhD, CEO
Hy Levitsky, MD, Pres., R&D
Luis Borges, PhD, CSO
Adrienne Farid, PhD, Chief Dev. Officer
Douglas Carr, VP, Fin. & Operations
- Contact Info
3675 Market St.
Philadelphia, PA 19104
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.